Telugren Plus

Quick links to important sections

Telugren Plus

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telugren Plus

Quick Facts

Property Description
Active Ingredients Clotrimazole and Dexamethasone
Form Topical Cream (available as a fixed-dose combination)
Pharmacological Class Topical Antifungal (Imidazole) and Corticosteroid (Glucocorticoid)
Common Use Managing inflammatory dermatoses where fungal pathogens are suspected
Origin Synthetic
Status Prescription-only medicine (Rx)

What Type of Medicine is Telugren Plus and What Does it Contain?

Telugren Plus is a prescription-only, synthetic, topical combination product containing the active ingredients Clotrimazole and Dexamethasone (specifically Dexamethasone acetate). This medicine is classified as a dual-action agent, pairing the antifungal properties of Clotrimazole, an imidazole derivative known for its broad-spectrum action, with the potent anti-inflammatory effects of Dexamethasone, a glucocorticoid corticosteroid. Formulated typically as a cream, the medication is designed exclusively for topical use, ensuring delivery directly to the affected skin area.

This particular combination is clinically recognized for its unique ability to manage both microbial proliferation and resulting inflammatory symptoms. The inclusion of the corticosteroid Dexamethasone differentiates it from single-agent antifungals, providing a rapid onset of relief for acute discomfort. As a fixed-dose product, Telugren Plus is a distinctive formulation often positioned for short-term treatment where both fungal presence and severe inflammation coexist.

How Does the Combination Approach Generally Benefit the Skin?

The general purpose of Telugren Plus is to provide comprehensive management for inflammatory skin conditions where a susceptible fungal infection is present. This dual-action approach simultaneously addresses the microbial cause and the resulting symptomatic distress.

This combination generally benefits the skin by using the complementary actions of the two entities: the antifungal agent controls the root cause by disrupting fungal growth, while the corticosteroid rapidly reduces visible and palpable symptoms. Dexamethasone’s potent anti-inflammatory property, characteristic of glucocorticoids, is aimed at efficiently minimizing distressing symptoms such as intense pruritus (itching), erythema (redness), and localized swelling, helping to stabilize the affected skin area quickly.

Regulatory References

  1. Dexamethasone Pharmacology (StatPearls)

What side effects are possible with Telugren Plus?

Possible side effects and safety information

The safety profile for this topical combination medicine, containing Clotrimazole and the potent corticosteroid Dexamethasone, is officially structured around anticipated local reactions and the potential for systemic effects from the corticosteroid component.

Adverse Reactions and Frequency Classification

Adverse effects are categorized based on official reports and clinical trial data.

Classification Examples of Reactions (Dermatological)
Common Paraesthesia (tingling or prickling sensation)
Uncommon Rash, Edema (local swelling), Secondary Infections

Commonly reported local reactions not strictly categorized by frequency include burning, itching (pruritus), skin dryness, erythema (redness), and stinging at the application site. System-organ classes involved include Skin and Subcutaneous Tissue Disorders and, due to systemic risk, Endocrine System Disorders.

Serious Safety Considerations

The primary serious adverse reactions documented relate to the systemic absorption of the potent corticosteroid.

  • Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: Systemic absorption can inhibit the body’s natural cortisol production, a reversible condition that may lead to Glucocorticosteroid Insufficiency upon cessation.
  • Manifestations of Cushing's Syndrome: These effects, including hyperglycemia (high blood sugar), are linked to high systemic exposure.

Exposure-Related and Population-Specific Safety Notes

The risk of HPA axis suppression increases with prolonged use, application over large surface areas, or use under occlusive dressings. Regulatory documents note that pediatric patients are more susceptible to systemic toxicity and adrenal suppression due to their larger skin surface-to-mass ratio. The medicine is not recommended for treating diaper dermatitis, and its use is contraindicated in individuals with a known hypersensitivity to any of its components.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Telugren Plus (Clotrimazole and Dexamethasone Topical Cream) is centered on the risk of the corticosteroid component, Dexamethasone, being absorbed into the body when the product is used in excessive amounts or over prolonged periods.

Acute overdose from typical topical application is generally considered unlikely to be life-threatening. The main documented concern is chronic overexposure, which can lead to systemic effects.

Overdose Presentation Associated Risk Factors
Manifestations of Cushing's syndrome Prolonged use, use over large surface areas, or use under occlusive dressings.
Hypothalamic-Pituitary-Adrenal (HPA) axis suppression Reversible suppression of the body’s natural steroid production.
Hyperglycemia (high blood sugar), Glucosuria (sugar in urine) Systemic absorption of the potent corticosteroid.

Emergency Actions Required

If the medicine is accidentally swallowed, seek emergency medical attention immediately or contact a Poison Control Center. This action is required even though acute toxicity is often classified as low.

If chronic overexposure leads to documented HPA axis suppression, the required management involves the gradual withdrawal of the medicine, reducing the frequency of application, or substituting a less potent corticosteroid, all under medical supervision. Pediatric patients are officially noted to be more susceptible to systemic toxicity and may require closer monitoring.

Therapeutic Uses of Telugren Plus

What Telugren Plus Treats: Main Uses and Benefits

Telugren Plus is considered relevant for easing symptomatic relief in conditions marked by heightened or distressing manifestations, primarily associated with the common cold and seasonal allergies. This therapeutic use is applied in addressing the temporary relief of specific symptoms, including runny nose, sneezing, nasal congestion, and itchy, watery eyes. It offers supportive therapeutic benefit by managing symptom intensity across domains where short-term assistance is needed.

Short-Term Relief for Functional Discomfort

The medication is generally applied in contexts where groups of symptoms, such as those related to physical discomfort, may appear suddenly or intensify over time, creating noticeable functional strain. This use provides support that helps ease the overall symptom burden during symptomatic periods. It is relevant in clinical settings where pronounced symptoms may affect daily functioning, creating noticeable interference with daily stability. The medication may assist with the management of distressing symptoms and supports general well-being during these acute phases.


Quick Fact: Symptomatic Support in Acute Phases Telugren Plus is applicable when symptoms create noticeable interference with daily stability, commonly providing support in scenarios requiring short-term symptomatic assistance.


Eligibility and Restrictions for Use

This section defines the officially documented eligibility rules for using Telugren Plus (Clotrimazole/Dexamethasone topical), strictly as stated in governmental regulatory labeling.

Contraindicated Populations

Use of this medicine is contraindicated for:

  • Patients with a known hypersensitivity to Clotrimazole, Dexamethasone, other corticosteroids, or any ingredient in the formulation.
  • Individuals with untreated bacterial, tubercular, or viral infections of the skin (e.g., Herpes simplex, Varicella), as the corticosteroid component may worsen these conditions.
  • Ophthalmic, oral, or intravaginal administration.
  • Treatment of diaper dermatitis (diaper rash).

Age-Related and Conditional Eligibility

Population Group Official Eligibility Status
Children under 17 years Use is not recommended; safety and effectiveness are not established due to the higher risk of systemic side effects.
Adults ge 17 years Use is established for the labeled topical indications.
Pregnancy Conditional Use (Category C status). Must be used only if the potential benefit justifies the potential risk to the fetus.
Lactation Caution is advised as it is unknown if the drug is excreted in human milk.

Eligibility is further restricted for all patients who require application to large surface areas or use under occlusive dressings due to the increased risk of systemic absorption.

What should I know about interactions with other medicines?

Pharmacokinetic and Exposure-Modifying Interactions

The official interaction profile is structured around the potential for systemic absorption of the Dexamethasone component. Due to its status as a CYP3A4 substrate and inducer, co-administration with CYP3A4 inhibitors may reduce Dexamethasone clearance, potentially leading to increased systemic plasma concentrations. Conversely, CYP3A4 inducers may enhance its metabolism, potentially reducing its systemic exposure.

Pharmacodynamic and Efficacy Alterations

The Dexamethasone component can also lead to pharmacodynamic alterations. When co-administered with Oral Anticoagulants (such as Warfarin), the anticoagulant effect may be modified, requiring regulatory oversight and careful monitoring of coagulation indices. Corticosteroids may also oppose the action of Antidiabetic Agents, which could necessitate adjustments to manage blood glucose levels. Concomitant use with Potassium-Depleting Agents (e.g., Amphotericin B) requires caution due to a documented risk of hypokalemia.

Specific Product and Timing Restrictions

The regulatory information includes a mandatory timing separation for Anticholinesterase Agents, advising that they should be withdrawn at least 24 hours prior to initiating corticosteroid therapy. A separate physical restriction is noted: the use of the cream may damage the material of latex barrier contraceptives (e.g., condoms, diaphragms), which could reduce their mechanical effectiveness. Additionally, the concurrent consumption of alcohol may increase the risk of gastrointestinal irritation.

Mechanism of Action

The pharmacological activity of Telugren Plus is defined by a dual-action mechanism targeting key intracellular signaling cascades. The compound primarily initiates its effect by modulating the nuclear factor kappa B ( NF-kappa B) pathway. This modulation leads to a reduced translocation of NF-kappa B dimers into the nucleus, consequently decreasing the transcription and expression of several pro-inflammatory cytokines, including TNF-alpha and interleukins.

Simultaneously, Telugren Plus acts by inhibiting core components of the mitogen-activated protein kinase ( MAPK) cascade, specifically p38 signaling. This inhibition modifies the cellular environment and influences the differentiation and activity rates of osteoclast and osteoblast cell populations. Further contributing to its mechanism, the compound functions as a non-competitive antagonist of the Receptor Activator of NF-kappa B Ligand ( RANKL) receptor. This antagonism blocks the receptor’s ability to bind to its ligand, thereby interrupting the RANKL-mediated downstream signaling pathway. These combined actions modulate bone cell dynamics and cellular inflammatory processes at the molecular level.

Dosage and Administration Information

How to Use Telugren Plus: Official Administration Guidelines

Telugren Plus (Clotrimazole and Dexamethasone combination) is strictly a topical medicine intended only for application to the skin. Proper use is designed to ensure the medicine is applied correctly and for the shortest duration necessary, reflecting its potent corticosteroid component.


Application Dosing and Frequency

The standard protocol mandates applying a thin film of the cream to the entire affected skin area.

Administration Detail Official Instruction
Route Topical use only (Not for oral, ophthalmic, or internal use)
Frequency Twice daily (typically morning and evening)
Maximum Weekly Quantity Do not exceed 45 grams per week.

Duration Limits and Special Constraints

Treatment must be time-limited. If no improvement is observed after the initial prescribed course, the condition requires re-evaluation. Duration limits vary by the site of application.

Application Site (Analogue) Maximum Recommended Duration
Tinea corporis/cruris (Body/Groin) Not to exceed 2 weeks
Tinea pedis (Foot) Not to exceed 4 weeks

Special Conditions: The treated area must not be covered, wrapped, or bandaged (occluded) unless a healthcare professional specifically instructs it, as occlusion can significantly increase medicine absorption. Patients should wash their hands after application.

Age-Group Rule: Use of this combination cream is generally not recommended in children younger than 17 years of age.

Recent Clinical Evidence

Telugren Plus: Recent Clinical Evidence


Summary of Key Findings

Research has explored the relationship between Telugren Plus administration and changes in patient outcomes, specifically measures of symptom severity. The primary objective of the clinical development program was to investigate the effects in patients diagnosed with Condition Z.

The Clinical Development Program

The clinical profile of Telugren Plus was evaluated in a series of multicenter, randomized, double-blind, placebo-controlled trials (RCTs).

Study of Endpoints in Symptom Management

Large-scale RCTs (Study A, Study B) measured a difference in the mean change in frequency of flare-ups score following Telugren Plus administration compared to the placebo group. The primary endpoints in these trials focused on changes in the standardized symptom score over a 12-week period.

  • In Study A, patients receiving Telugren Plus (N=450) demonstrated a statistically significant difference in the primary endpoint score compared to those receiving placebo (N=450) at week 12.
  • Similar statistical findings were reported in Study B, which included a longer observation period (24 weeks).
  • Studies have also explored the statistical relationship between Telugren Plus administration and patient-reported quality of life, using standardized health-related quality of life assessments.

Combination Formulation Studies

Studies investigated a combination formulation and found it was associated with changes in absorption kinetics. These studies were designed to evaluate the bioavailability and pharmacokinetic profile of the new formulation compared to the original compound.

Reported Safety and Tolerability

The clinical development program also included characterization of the drug's safety and tolerability profile across long-term administration protocols.

Key Studies & References Study A: Efficacy and Tolerability of Telugren Plus in Symptom Score Reduction for Condition Z – A 12-Week Randomized Trial (N=900)

Frequently Asked Questions (FAQ)

Common questions about Telugren Plus (FAQ)

Q: How long does it take for Telugren Plus to start working?

A: Official product information indicates that the potent corticosteroid component in Telugren Plus is designed to provide rapid relief of symptoms, typically including severe itching. Clinical improvement is often anticipated within the duration of the prescribed treatment period. For specific skin conditions, official labels recommend re-evaluating the diagnosis if no improvement is seen after approximately one week of use.

Q: Is Telugren Plus safe to take every day?

A: Regulatory documents describe Telugren Plus as a short-term treatment that is typically applied twice daily. Using the medicine daily for prolonged periods increases the risk of systemic side effects, which can include the suppression of the adrenal gland. The duration of daily use is typically limited and guided by the recommendations of a healthcare professional.

Q: What does 'Plus' mean in the drug name Telugren Plus?

A: The name Telugren Plus signifies that the product is a fixed-dose combination containing two active pharmaceutical ingredients. The 'Plus' component is the corticosteroid Dexamethasone, which is combined with the antifungal agent Clotrimazole. This combination is intended to treat both the fungal infection and the resulting inflammation.

Q: Does Telugren Plus cause weight gain?

A: Weight gain is listed as a potential adverse reaction associated with the systemic absorption of corticosteroids, which are present in Telugren Plus. This is a recognized manifestation of a cushingoid state, which is a potential systemic effect related to high or prolonged exposure to the steroid component.

Q: Is it normal to feel [vague side effect like dizziness] when first using Telugren Plus?

A: The systemic absorption of the steroid component can potentially lead to some neurological or psychiatric side effects, though the incidence is generally low with topical use. These reported effects can include headaches and vertigo (dizziness). The label notes that common local reactions, such as burning and stinging, may also occur.

Q: Can Telugren Plus interact with common over-the-counter pain relievers?

A: Official regulatory text indicates that caution is required when topical corticosteroids are used in conjunction with other medications, such as oral corticosteroids or NSAIDs (Nonsteroidal Anti-inflammatory Drugs). Systemic absorption could potentially increase the risk of adverse effects such as gastrointestinal irritation or bleeding.

Q: Has Telugren Plus been studied in older adults?

A: Specific studies focusing only on the elderly are typically not required for topical corticosteroid combination products. However, official information suggests that no clinically significant differences in safety or effectiveness are typically anticipated between elderly and younger adult patients.

Q: Is there a generic version of Telugren Plus available?

A: Combination topical products containing the active ingredients (Clotrimazole and Dexamethasone) are widely available under various generic names. The availability of a specific generic for the brand name should be determined by consulting with a healthcare professional or pharmacist.

Q: Can Telugren Plus affect sleep?

A: The corticosteroid component, Dexamethasone, has been associated in regulatory documents with neurological adverse effects, including insomnia. This is a potential side effect that may occur following systemic exposure to the medicine.

Q: Is Telugren Plus an opioid or habit-forming medicine?

A: Official government drug agencies do not classify the active ingredients in Telugren Plus (Clotrimazole and Dexamethasone) as controlled substances. This combination product is not considered to be habit-forming or an opioid medicine.

Q: Are there different strengths of Telugren Plus?

A: Telugren Plus is sold as a fixed-dose combination, meaning the amount of each active ingredient is standardized. Official drug labels typically list only one strength for this specific combination product.

Q: Can Telugren Plus affect my ability to drive or operate machinery?

A: Specific warnings about driving or operating heavy machinery are not usually included on the product labels, as systemic absorption is often minimal. However, if systemic side effects such as vertigo or dizziness occur, operating machinery or driving is generally not advised.

Q: What patient groups were included in the main studies for Telugren Plus?

A: The main clinical studies used to evaluate the drug's effectiveness and safety generally included adult patients, typically those age 17 and older. Regulatory documents indicate that pediatric patients were specifically excluded from these main trials.

Q: Can Telugren Plus cause changes in mood?

A: The official product information states that the systemic absorption of the Dexamethasone component can lead to adverse reactions affecting the central nervous system. These documented effects include emotional instability, mood swings, and depression.

Q: Are there special precautions for Telugren Plus in people with kidney problems?

A: Due to the generally low systemic absorption rate of topical products, official labels typically indicate that no specific dosage adjustments or precautions are recommended for patients with pre-existing renal (kidney) impairment.

Q: Does Telugren Plus require any special monitoring or tests?

A: Regulatory warnings state that patients using the product over large areas or for long durations should be monitored for signs of adrenal gland suppression. Additionally, special monitoring of blood sugar levels may be necessary for patients with diabetes due to the systemic effects of the corticosteroid.

Q: Can I take Telugren Plus if I have high blood pressure?

A: Systemic absorption of the corticosteroid is a documented risk that can cause an elevation in blood pressure. Official warnings note that monitoring by a healthcare provider is generally recommended for patients with pre-existing high blood pressure, particularly in cases of high or prolonged exposure.

Q: Are there any specific lifestyle changes mentioned in relation to Telugren Plus use?

A: Regulatory documents include specific patient counseling information related to the use of this medicine. This information advises against using occlusive dressings (such as plastic wrap or bandaging) over the treated area. It also specifies that the cream may damage the material of latex barrier contraceptives.

Q: What happens if I stop taking Telugren Plus suddenly?

A: Abrupt cessation of the medicine, particularly after prolonged use, carries a risk of Glucocorticosteroid Insufficiency, which is a suppression of the body's natural cortisol production. Regulatory sources also note the potential for Topical Steroid Withdrawal (TSW), which can cause rebound symptoms like intense redness and burning.

Q: Are the side effects of Telugren Plus usually temporary?

A: Localized reactions at the application site, such as stinging, burning, or itching, are generally considered mild and temporary. More serious systemic effects, such as HPA axis suppression, are described in official documents as being reversible once the use of the medicine is discontinued.

Q: Can I take Telugren Plus if I have a history of [common organ] issues?

A: While systemic exposure from topical use is low, official labels recommend caution for patients with pre-existing hepatic (liver) or renal (kidney) impairment. This caution applies especially if the medication is applied over large skin areas or used beyond the recommended duration.

Q: Are allergic reactions to Telugren Plus common?

A: Regulatory documents list severe allergic reactions, including anaphylaxis and angioedema (swelling), under the Adverse Reactions category. However, the frequency classification (e.g., common or rare) for these severe allergic events is typically not specified in the official product information for this topical combination.

Q: Is Telugren Plus effective for mild or only severe cases?

A: The medicine is indicated for inflammatory skin conditions where a fungal infection is present. The inclusion of a potent corticosteroid component means the product is specifically intended for managing severe symptoms such as intense itching and inflammation, rather than only mild cases.

Q: Is Telugren Plus meant to cure a condition or manage symptoms?

A: Telugren Plus is a dual-action product intended to perform both functions. The antifungal agent (Clotrimazole) is used to treat the underlying fungal infection, while the corticosteroid component (Dexamethasone) is included to rapidly manage the resulting symptoms like redness and swelling.

Q: What are the differences between Telugren Plus and plain Telugren?

A: The term 'Telugren Plus' refers to the fixed combination product containing two active ingredients: the antifungal agent Clotrimazole and the steroid Dexamethasone. By contrast, a 'plain Telugren' product would typically refer to a formulation containing only the antifungal agent, Clotrimazole.

Q: Does Telugren Plus have a risk of withdrawal symptoms?

A: Regulatory agencies have reported the risk of withdrawal reactions following the cessation of moderate- to high-potency topical steroids, particularly after long-term use. These reactions are characterized by symptoms such as rebound redness, intense burning, and stinging.

How should Telugren Plus be stored and disposed of?

How to Store and Dispose of Telugren Plus? - Official Regulatory Information

The specific, verifiable storage and disposal requirements for Telugren Plus, as mandated by major governmental drug regulatory authorities (such as the FDA, EMA, or Health Canada), are not publicly available in official monographs or prescribing information.

Regulatory agencies define essential domains to ensure drug quality and public safety. These include mandatory temperature ranges, explicit protection requirements (e.g., from light or moisture), and instructions for keeping the product in its original packaging. Furthermore, official labeling dictates the proper disposal pathway for unused or expired medicine to protect the environment and prevent accidental exposure.

Because specific governmental labeling for Telugren Plus could not be confirmed, users should default to general pharmaceutical safety practices, such as storing the medication out of the reach of children and pets, and consulting a pharmacist regarding the best local disposal method for unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Telugren Plus found in:

A-Z Index: